Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and Challenges

X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disease caused by pathogenic variants in <i>ABCD1</i> resulting in defective peroxisomal oxidation of very long-chain fatty acids. Most male patients develop adrenal insufficiency and one of two neurologic phenotypes: a rapidly...

Full description

Saved in:
Bibliographic Details
Main Authors: Craig V. Baker (Author), Alyssa Cady Keller (Author), Richard Lutz (Author), Karen Eveans (Author), Krystal Baumert (Author), James C. DiPerna (Author), William B. Rizzo (Author)
Format: Book
Published: MDPI AG, 2022-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_41e28ecea72444f0995ecb5c3c0435e1
042 |a dc 
100 1 0 |a Craig V. Baker  |e author 
700 1 0 |a Alyssa Cady Keller  |e author 
700 1 0 |a Richard Lutz  |e author 
700 1 0 |a Karen Eveans  |e author 
700 1 0 |a Krystal Baumert  |e author 
700 1 0 |a James C. DiPerna  |e author 
700 1 0 |a William B. Rizzo  |e author 
245 0 0 |a Newborn Screening for X-Linked Adrenoleukodystrophy in Nebraska: Initial Experiences and Challenges 
260 |b MDPI AG,   |c 2022-04-01T00:00:00Z. 
500 |a 10.3390/ijns8020029 
500 |a 2409-515X 
520 |a X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disease caused by pathogenic variants in <i>ABCD1</i> resulting in defective peroxisomal oxidation of very long-chain fatty acids. Most male patients develop adrenal insufficiency and one of two neurologic phenotypes: a rapidly progressive demyelinating disease in mid-childhood (childhood cerebral X-ALD, ccALD) or an adult-onset spastic paraparesis (adrenomyeloneuropathy, AMN). The neurodegenerative course of ccALD can be halted if patients are treated with hematopoietic stem cell transplantation at the earliest onset of white matter disease. Newborn screening for X-ALD can be accomplished by measuring C26:0-lysophosphatidylcholine in dried blood spots. In Nebraska, X-ALD newborn screening was instituted in July 2018. Over a period of 3.3 years, 82,920 newborns were screened with 13 positive infants detected (4 males, 9 females), giving a birth prevalence of 1:10,583 in males and 1:4510 in females. All positive newborns had DNA variants in <i>ABCD1</i>. Lack of genotype-phenotype correlations, absence of predictive biomarkers for ccALD or AMN, and a high proportion of <i>ABCD1</i> variants of uncertain significance are unique challenges in counseling families. Surveillance testing for adrenal and neurologic disease in presymptomatic X-ALD males will improve survival and overall quality of life. 
546 |a EN 
690 |a adrenoleukodystrophy 
690 |a adrenomyeloneuropathy 
690 |a newborn screening 
690 |a X-ALD 
690 |a <i>ABCD1</i> 
690 |a peroxisomal fatty acid oxidation 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n International Journal of Neonatal Screening, Vol 8, Iss 2, p 29 (2022) 
787 0 |n https://www.mdpi.com/2409-515X/8/2/29 
787 0 |n https://doaj.org/toc/2409-515X 
856 4 1 |u https://doaj.org/article/41e28ecea72444f0995ecb5c3c0435e1  |z Connect to this object online.